Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

Cholinergic & noradrenergic contributions to presymptomatic AD progression

Project Overview

Alzheimer’s Association International Research Grant Program: Alzheimer’s Association Research Grant (AARG)

The development of approaches to aid early detection of the transition from healthy aging to mild cognitive impairment and Alzheimer’s disease (AD) is critically important for developing targeted strategies to halt or slow disease progression. Post-mortem studies have identified AD-related brain changes years and even decades before the age of typical AD onset, when clinically detectable cognitive changes are observed. These earliest brain changes have been identified in subcortical regions linked to specific neurotransmitter systems (e.g., the cholinergic basal forebrain and the adrenergic locus coeruleus). Whether these changes follow a predictable temporal sequence, progressing from an origin site to other subcortical and cortical regions is unknown. We will study this question using advanced neuroimaging methods in a cohort of older adults who are at elevated risk for AD, but who remain asymptomatic. The goal of this research is to track the unfolding of the AD-related pathological cascade, to identify specific staging of the degenerative processes from subcortical to cortical brain regions. This knowledge can be used to surveil for and detect neuropathological changes occurring at the very earliest disease stages, thereby expanding the window for novel treatment and intervention approaches.

Principal Investigator

Nathan Spreng , McGill University

Partners and Donors

Alzheimer's Association

Project Ongoing

Cholinergic & noradrenergic contributions to presymptomatic AD progression

  • Program Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    Alzheimer’s Association International Grant Program

  • Province

    Québec

  • Start Date

    2022

  • Total Grant Amount

    $188,892

  • Health Canada Contribution

    $94,446

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co